

Hutchison MediPharma Pipeline

■ CANCER ■ AUTO-IMMUNE

Drug Candidate	Exploratory Candidate	Preclinical Tox & CMC	Phase I	Phase II	Phase III	
HMPL-004 (Ulcerative colitis)					▶	Global Phase IIb completed - met all endpoints including clinical response, alongside an excellent safety profile.
HMPL-004 (Crohn's disease)					▶	Global Phase II completed - showed an encouraging trend of efficacy and an excellent safety profile.
HMPL-011 (Inflammation)			▶			Australia Phase I ongoing - Novel, first-in-class cytokine modulator. Good efficacy and pharmacokinetics in RA animal models.
HMPL-012 (Cancer)			▶			Novel kinase inhibitor - Broad-spectrum anti-tumor agent with unique kinase profile. IND submitted to SFDA for review.
HMPL-013 (Cancer)			▶			Novel Kinase inhibitor - Highly selective and potent agent. IND submitted to SFDA for review.
HMPL-813 (Cancer)		▶				Novel kinase inhibitor - highly potent with good kinase selectivity. Preparing IND-enabling evaluations.
HMPL-309 (Cancer)		▶				Novel kinase inhibitor - improved activity against resistance. Preparing IND-enabling evaluations.